Xeroshield has now completed its proof of market study for a new preventative technology for tackling ticks and Lyme disease and submitted this to the UK Technology Strategy Board.

We are extremely grateful to all organisations and individuals that contributed to the successful completion of the study. Anyone interested in reading a summary of the main conclusions from the study can access a summary report by clicking on the following web-link:

Xeroshield Summary Report – Ticks and Lyme Disease Study 2012

Xeroshield is now actively seeking support and funding to be able to progress its technology to the next stage of development and would welcome contact from anyone interested in discussing this in further detail:

Contact: Bruce Alexander, Managing Director

Xeroshield Ltd

Wallace Building

Roslin BioCentre

Roslin

Midlothian

EH25 9PP

E-mail: bruce.alexander@xeroshield.com

Tel: 0131 200 6377

Reg. No. SC286434

Thank you for your interest and support.